Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PRISM BioLab, Lilly Enter PPI Discovery Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

PRISM BioLab, Lilly Enter PPI Discovery Collaboration

Aims to discover oral inhibitors of protein-protein interaction targets leveraging PRISM BioLab's PepMetics technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PRISM BioLab, Co. Ltd., a discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, has entered into a license and collaboration agreement with Eli Lilly and Co.
 
PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM’s PepMetics technology. Lilly has the option to add up to two more targets and is responsible for clinical development and commercialization of resulting products. PRISM will receive upfront payments and is eligible to receive up to $660 million in preclinical, clinical and commercial development milestones, as well as royalties on product sales.
 
“We are very excited to enter into this collaboration with Lilly as we apply our technology to expand the field of drug discovery into a novel approach to drug the PPI targets,” said Dai Takehara, President and Chief Executive Officer of PRISM Biolab. “Our PepMetics technology holds promise to change the current paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics